Follow
Francesco Castelli
Francesco Castelli
Verified email at unibs.it
Title
Cited by
Cited by
Year
Combination antiretroviral therapy and the risk of myocardial infarction
Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group
New England Journal of Medicine 349 (21), 1993-2003, 2003
20712003
Auto-antibodies against type I IFNs in patients with life-threatening COVID-19.
H Lab, NU Im
Science. 2020 Sep 24:eabd4585. doi: 10.1126/science.abd4585, 2020
1768*2020
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19.
Science. 2020 Sep 24:eabd4570. doi: 10.1126/science.abd4570, 2020
1548*2020
Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics
E Petersen, M Koopmans, U Go, DH Hamer, N Petrosillo, F Castelli, ...
The Lancet infectious diseases 20 (9), e238-e244, 2020
10582020
Towards tuberculosis elimination: an action framework for low-incidence countries
K Lönnroth, GB Migliori, I Abubakar, L D'Ambrosio, G De Vries, R Diel, ...
European Respiratory Journal 45 (4), 928-952, 2015
7672015
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy
P Toniati, S Piva, M Cattalini, E Garrafa, F Regola, F Castelli, ...
Autoimmunity reviews 19 (7), 102568, 2020
7592020
Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature
A Ammassari, MP Trotta, R Murri, F Castelli, P Narciso, P Noto, J Vecchiet, ...
JAIDS-HAGERSTOWN MD- 31 (5; SUPP), S123-S127, 2002
6552002
GeoSentinel surveillance of illness in returned travelers, 2007–2011
K Leder, J Torresi, MD Libman, JP Cramer, F Castelli, P Schlagenhauf, ...
Annals of internal medicine 158 (6), 456-468, 2013
5022013
Knowledge, attitudes and practices in travel-related infectious diseases: the European airport survey
K Van Herck, F Castelli, J Zuckerman, H Nothdurft, P Van Damme, ...
Journal of travel medicine 11 (1), 3-8, 2004
4582004
Mapping the human genetic architecture of COVID-19
Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ...
Nature 600 (7889), 472-477, 2021
3972021
Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes
B Ledergerber, PLATO collaboration
The Lancet 364 (9428), 51-62, 2004
3882004
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 …
JM Llibre, CC Hung, C Brinson, F Castelli, PM Girard, LP Kahl, EA Blair, ...
The Lancet 391 (10123), 839-849, 2018
3372018
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2 …
P Cahn, JS Madero, JR Arribas, A Antinori, R Ortiz, AE Clarke, CC Hung, ...
The Lancet 393 (10167), 143-155, 2019
2952019
Management of patients on dialysis and with kidney transplantation during the SARS-CoV-2 (COVID-19) pandemic in Brescia, Italy
F Alberici, E Delbarba, C Manenti, L Econimo, F Valerio, A Pola, C Maffei, ...
Kidney International Reports 5 (5), 580-585, 2020
2892020
Drivers of migration: why do people move?
F Castelli
Journal of travel medicine 25 (1), tay040, 2018
2812018
Steroid‐responsive encephalitis in coronavirus disease 2019
A Pilotto, S Odolini, S Masciocchi, A Comelli, I Volonghi, S Gazzina, ...
Annals of neurology 88 (2), 423-427, 2020
2592020
Factors associated with surgical mortality and complications among patients with and without coronavirus disease 2019 (COVID-19) in Italy
F Doglietto, M Vezzoli, F Gheza, GL Lussardi, M Domenicucci, ...
JAMA surgery 155 (8), 691-702, 2020
2562020
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
E Kyriazopoulou, G Poulakou, H Milionis, S Metallidis, G Adamis, ...
Nature medicine 27 (10), 1752-1760, 2021
2232021
Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths
P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, J Manry, ...
Science immunology 6 (62), eabl4340, 2021
2102021
An immune-based biomarker signature is associated with mortality in COVID-19 patients
MS Abers, OM Delmonte, EE Ricotta, J Fintzi, DL Fink, AAA de Jesus, ...
JCI insight 6 (1), 2021
2062021
The system can't perform the operation now. Try again later.
Articles 1–20